Table 1 Baseline characteristics
Variable | All patients (n = 35) |
|---|---|
Age at diagnosis (years) | 52.5 ± 12.7 |
Male sex | 26 (74.3%) |
Caucasian ethnicity | 32 (91.4%) |
Body mass index (m2/kg) | 27.5 ± 3.7 |
Symptoms prior to first evaluation | |
Chest pain | 7 (20.0%) |
Palpitations | 17 (48.6%) |
Syncope | 3 (8.6%) |
Dizziness | 6 (17.1%) |
NYHA functional class (I/II/III/IV) | 12/18/5/0 |
Comorbidities | |
Hypertension | 9 (25.7%) |
Diabetes mellitus | 1 (2.9%) |
Coronary artery disease | 1 (2.9%) |
Extra-cardiac sarcoidosis histologically or cytologically confirmed | 33 (94.3%) |
Extra-cardiac organ involvement | |
Bilateral hilar lymphadenopathy | 29 (82.9%) |
Pulmonary | 33 (94.3%) |
Skin | 1 (2.9%) |
Neurologic | 5 (14.3%) |
Liver | 3 (8.6%) |
Ocular | 5 (14.3%) |
Laboratory results | |
CRP (mg/L) | 3.0 [2.0–4.5] |
NT-proBNP (pg/mL) (n = 28) | 44.0 [26.5–120.5] |
ACE (U/L) | 46.0 [33.0–68.0] |
sIL-2R (pg/mL) | 4057 [2887–5745] |
Electrocardiogram results (n = 32) | |
Sinus rhythm | 31 (96.9%) |
PQ-interval > 200 ms | 4 (12.5%) |
QRS duration (ms) | 98.0 [91.0–112.0] |
Left bundle branch block | 0 (0.0%) |
Right bundle branch block | 4 (12.5%) |
Left ventricular ejection fraction (%) | 60.0 [55.0–62.0] |
Immunosuppressive therapy at baseline | 14 (40%) |
Anti-arrhythmic drugs | 6 (17.1%) |
ACE-inhibitors or ARBs | 11 (31.4%) |